Market Cap (In USD)
79.09 Million
Revenue (In USD)
170 Thousand
Net Income (In USD)
-28.29 Million
Avg. Volume
211.18 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.6-16.6
- PE
- -
- EPS
- -
- Beta Value
- -3.16514
- ISIN
- US36870H1032
- CUSIP
- CIK
- 1231457
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Thomas Zindrick J.D.
- Employee Count
- -
- Website
- https://www.genelux.com
- Ipo Date
- 2023-01-26
- Details
- Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
More Stocks
-
DUTRONDutron Polymers Limited
DUTRON
-
3105
-
UDRUDR, Inc.
UDR
-
AMPX-WTAmprius Technologies, Inc.
AMPX-WT
-
PHX
-
BRSA
-
3758Aeria Inc.
3758
-
PHD